Asset
Nogapendekin Alfa Inbakicept
Revenue
No revenue reported in loaded filings.
Clinical trials (47)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06710288 | phase2 | recruiting | 2024-11-06 | 2027-05-01 | ImmunityBio, Inc. | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer |
| NCT02138734 | phase1_2 | active_not_recruiting | 2014-07-21 | 2026-09-30 | ImmunityBio, Inc. | A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
| NCT04927884 | phase1_2 | terminated | 2021-09-08 | 2022-09-13 | ImmunityBio, Inc. | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies |
| NCT07108036 | phase2 | recruiting | 2025-11-14 | 2026-10-01 | ImmunityBio, Inc. | A Study to Assess Anktiva in Patients With Long Covid-19. |
| NCT07123727 | phase2 | recruiting | 2025-09-04 | 2026-07-01 | ImmunityBio, Inc. | A Study to Examine Anktiva for the Treatment of COVID-19. |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 761336 | BLA | Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. |
Marketed products (1)
- ANKTIVA